Case Reports in Oncological Medicine
Volume 2019 (2019), Article ID 3868790, 1 page
https://doi.org/10.1155/2019/3868790

Corrigendum

Corrigendum to “Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience”

Vidhya Karivedu,¹ Ihab Eldessouki,¹ Zelia Correa,² Ahmad Taftaf,¹ Zheng Zhu,³ Abouelmagd Makramalla,⁴ and Nagla Abdel Karim⁵

¹Department of Internal Medicine, Division of Hematology/Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA
²Ocular Oncology Service, Department of Ophthalmology, University of Cincinnati College of Medicine, USA
³Department of Biostatistics and Bioinformatics, Department of Environmental Health, College of Medicine, University of Cincinnati, Cincinnati, OH, USA
⁴Division of Vascular and Interventional Radiology, University of Cincinnati College of Medicine, Cincinnati, OH, USA
⁵Department of Internal Medicine, Division of Hematology/Oncology, Medical College of Georgia-Augusta University, Augusta, GA, USA

Correspondence should be addressed to Vidhya Karivedu; kariveva@ucmail.uc.edu

Received 28 July 2019; Accepted 23 August 2019; Published 28 October 2019

Copyright © 2019 Vidhya Karivedu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience” [1], Dr. Zelia Correa was missing from the authors’ list. Dr. Zelia Correa commented on the article and referred the patient population in the study. The corrected authors’ list and affiliations are shown above.

References

V. Karivedu, I. Eldessouki, A. Taftaf, Z. Zhu, A. Makramalla, and N. A. Karim, “Nivolumab and ipilimumab in the treatment of metastatic uveal melanoma: a single-center experience,” Case Reports in Oncological Medicine, vol. 2019, Article ID 3560640, 8 pages, 2019.